Allsup Supports Cervical Cancer Awareness Month With SSDI Expertise For Patients
January 16, 2025 11:45 ET
|
Allsup
Belleville, Illinois, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Allsup, the nation’s leading provider of Social Security Disability Insurance (SSDI) representation services, is shining a light on Cervical...
University Cancer & Blood Center physicians recognized among Atlanta’s Top Doctors in Modern Luxury Medicine + Doctors magazine
January 15, 2025 14:14 ET
|
University, Cancer and Blood Center
Four physicians from University Cancer & Blood Center are recognized as Top Doctors in Modern Luxury Medicine + Doctors magazine.
AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones
January 15, 2025 09:05 ET
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces –...
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI
January 13, 2025 08:30 ET
|
Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company dedicated to advancing new cancer therapies based on novel...
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
January 13, 2025 08:00 ET
|
Immuneering Corporation
Immuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic Cancer
Bioxytran’s Cancer Preprint Reveals Potential to Enhance Most Immunotherapy Drugs
January 10, 2025 10:21 ET
|
BIOXYTRAN, INC.
BOSTON, MASSACHUSETTS, Jan. 10, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat viral...
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
January 07, 2025 08:00 ET
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
January 07, 2025 08:00 ET
|
Hummingbird Bioscience
Hummingbird Bioscience Licenses Novel Antibodies to Immunome
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104; Plans to Expand Trial with Additional Arms
January 07, 2025 07:00 ET
|
Immuneering Corporation
Immuneering Announces Positive Data Update from Three Pancreatic Cancer Arms of Ongoing Phase 2a Trial of IMM-1-104
Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 06, 2025 16:05 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with...